Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.33 |
| ▸ | KDM6A | O15550 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937494 | 0.82 | LMNA (0.46) | LPOMEN1KMT2AL3MBTL1CYP2C9 | |
| SCHEMBL7586824 | 0.79 | KDM4E (0.35) | KDM4EMEN1KMT2ABRD4BRPF1 | |
| SCHEMBL16130857 | 0.71 | P2RX4 (0.45) | MEN1KMT2AL3MBTL1P2RX4ALDH1A1 | |
| SCHEMBL24244797 | 0.71 | LPO (0.63) | LPOKDM4EMEN1KMT2ABRD4 | |
| SCHEMBL100263 | 0.66 | CRBN (0.44) | KDM4EMEN1KMT2ABRD4BRPF1 | |
| SCHEMBL3654048 | 0.65 | MYC (0.41) | LPOKDM4EMEN1KMT2AL3MBTL1 | |
| Water SCHEMBL6505685 | 0.65 | CRBN (0.43) | KDM4EMEN1KMT2ABRD4BRPF1 | |
| SCHEMBL23457423 | 0.65 | L3MBTL1 (0.40) | LPOKDM4EMEN1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7524493 | 0.65 | CRBN (0.43) | KDM4EMEN1KMT2ABRD4BRPF1 | |
| SCHEMBL2078819 | 0.63 | CRBN (0.37) | KDM4EBRD4BRPF1KDM6AKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009985-A1 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | CURELAB ONCOLOGY INC (US) | 2022-01-13 | — | — | US | disclosed |
| WO-2021071979-A1 | COMPOSITIONS AND METHODS FOR INCREASING EPITHELIAL BARRIER FUNCTION | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200338176-A1 | METHODS AND COMPOSITIONS RELATING TO P62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER | CURELAB ONCOLOGY INC (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3089753-B1 | METHODS AND COMPOSITIONS RELATING TO P62/SQSTM1 FOR THE TREATMENT AND PREVENTION OF INFLAMMATION-ASSOCIATED DISEASES | CURELAB ONCOLOGY INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10716837-B2 | Methods and compositions relating to P62 for the treatment and prophylaxis of cancer | CURELAB ONCOLOGY, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190153056-A1 | Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases | CURELAB ONCOLOGY INC (US) | 2019-05-23 | — | — | US | disclosed |
| EP-2750694-B1 | METHODS AND COMPOSITIONS RELATING TO P62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER | CURELAB ONCOLOGY INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9717781-B2 | Methods and compositions relating to P62 for the treatment and prophylaxis of cancer | CURELAB ONCOLOGY, INC. | 2017-08-01 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170043002-A1 | METHODS AND COMPOSITIONS RELATING TO P62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER | CURELAB ONCOLOGY, INC. | 2017-02-16 | — | — | US | disclosed |
| EP-1294871-A1 | SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF | Amgen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001068859-A9 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1265924-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1266002-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002094859-A2 | MAGE-A1 PEPTIDES FOR TREATING OR PREVENTING CANCER | AVENTIS PASTEUR LIMITED (CA) | 2002-11-28 | — | — | WO | disclosed |
| EP-1238077-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001098497-A1 | SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF | AMGEN, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001068859-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068705-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001044472-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | LPO 3801/4885KDM4E 1053/4885MEN1 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.